You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Medications for Synthetic Cannabinoid Abuse

    SBC: PAFOSPharma, LLC            Topic: R41

    PROJECT SUMMARY ABSTRACT In response to PAthis Phase I STTR proposal will aim at developing pharmacotherapies that can act aslife savermedications to counteract the neurotoxic effects of synthetic cannabinoidsSCsTowards this goalwe will synthesize CB R antagonists with fast onsets of action that can be administered in an emergency roomERsituationThe rationale is based on the successful soft agonis ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. The Antibody Registry: A Community Authority for Antibody Research Resource Identifiers

    SBC: SCICRUNCH            Topic: 300

    Project SummaryOne of the most glaring yet easily addressable gaps in our current scientific workflow and publication system is improving the way that methods are reportedin particularthe lack of key methodological details necessary for interpreting and reproducing a studyMost authors continue to cite the name of the reagentlike an antibody using the vendorand the city where the vendor is locatedb ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction

    SBC: ImmunoChem Therapeutics, LLC            Topic: 102

    PROJECT SUMMARY Cognitive decline and deterioration of long term cognitive performance are major side effects of CNS cancer treatmentBrain metastases are the most common CNS malignancies and a common cause of morbidity and mortality in aboutof all cancer patients with systemic diseaseaffecting overpatients in the US annuallyAs most systemic chemotherapy agents do not cross the blood brain barriert ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Developing a Scalable Manufacturing Process for an Oral Bacteriophage Product that Prevents Cholera

    SBC: PhagePro, Inc.            Topic: NIAID

    PROJECT SUMMARY Cholera is an acute and severe disease caused by the bacterium Vibrio cholerae that is spread primarily through contaminated water sources due to a lack of adequate sanitation infrastructureThe World Health Organization estimates that there are at leastmillion cases globally per yearpercent of which are spread through household transmissionCurrent prevention methods require signifi ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel Two-in-One Approach to Administer Surfactant and Provide Airway Support to VLBW Infants

    SBC: BB MEDICAL SURGICAL, INC.            Topic: NICHD

    PROJECT SUMMARYABSTRACT Every yearvery low birth weightVLBWandltginfants are born in the U SThe use of surfactant dramatically decreases morbidity and mortality due to respiratory distress syndromeRDSin VLBW infantsCurrent standards for surfactant administration require the infant to be intubatedso that surfactant can be delivered to the trachea and lungsIntubating a VLBW infant is challenging and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Lead Optimization of Peripheral CB1 Neutral Antagonists for Renal Diseases

    SBC: MAKScientific LLC            Topic: 400

    RESEARCH andampRELATEDUnitPROJECT SUMMARY ABSTRACT In response to PAthe aim of this Phase I STTR proposal is to optimize and develop peripherally actingcannabinoidreceptorCB Rneutral antagonists displaying favorable therapeutic profiles for treating diabetic nephropathyDNDN is a chronic diabetic kidney disease and affectstypeand typediabetic patientsIt is characterized by persistent albuminuria an ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Ultra-sensitive Rapid Diagnostic Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis

    SBC: NANOCOMPOSIX, INC.            Topic: NIAID

    Project SummaryAbstract Lymphatic filariasisLFcaused by the parasitic filarial worm Wuchereria bancroftiis a disfiguring and debilitating neglected tropical disease that affectsmillion people incountriesThrough the World Health Organization sWHOGlobal Program for the Elimination of Lymphatic FilariasisGPELFbillion drug regimens have been distributed via mass drug administrationMDAtomillion people ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Software for Determining Proteoform Heterogeneity and Protein Expression Fidelity

    SBC: GENNEXT TECHNOLOGIES, INC.            Topic: 400

    The importance of large protein drugsbiopharmaceuticalsand their generic counterpartsknown as biosimilarshas created a need for improved analytics to facilitate biopharmaceutical research and to combat adverse drug reactionsThe recombinant protein expression process is inherently prone to low level errors resulting in sequence variants caused by amino acid misincorporationwhich are observed in bot ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Integrated Microbial Screening and Antimicrobial Susceptibility Test on Microfluidic Digital Array for Diagnosis of Urinary Tract Infections

    SBC: Combinati Incorporated            Topic: NIAID

    Abstract COMBiNATi will work with Stanford University to bring the world s first integrated ID AST UTI diagnostic platform to the market by combining COMBiNATi sone clickcost effective dPCR platform with Stanford s pathogen identificationIDHRMA algorithm for broad detectiondeep characterization and absolute quantification of UTI pathogensBy the end of the Phaseprojectwe will deliver the prototype ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government